Fundz

Who to call at bit.bio, and when

Fundz watches for the moments bit.bio starts buying, and tells you who to reach.

  • An alert the day bit.bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at bit.bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at bit.bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Launchbit.bio Successfully Defends Patent for opti-ox™ Cell Programming Technology to Enhance Pluripotent Stem Cell Applications

Oct 16, 2024
CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments

Product Description

bit.bio announces the successful defense of its European patent for opti-ox, a technology that allows for deterministic programming of pluripotent stem cells. The ruling strengthens bit.bio's position as a leader in the field of iPSC-derived cell manufacturing, with patents secured in multiple major markets.

Company Information

Company

bit.bio

Location

Cambridgeshire, England, United Kingdom

About

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment bit.bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Abbey hidden

hidden
hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for bit.bio's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

bit.bio shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.